Prolongation of murine vascularized heart allograft survival by recipient-specific anti-major histocompatibility complex class II antibody
Smith, R.M.; Chen, Z.K.; Foulkes, R.; Metcalfe, S.M.; Wraith, D.C.
Transplantation 64(3): 525-528
1997
ISSN/ISBN: 0041-1337 PMID: 9275122 Document Number: 477068
Background. Antibodies targeting recipient major histocompatibility complex (MHC) class II molecules have been demonstrated to be effective at prolonging allograft survival. However, antigen-presenting cell depletion would explain this effect and has not been definitively excluded as the mechanism of action of such antibodies. We have studied an anti-MHC class II antibody (OX6) proven to be noncytotoxic in the recipient strain used. Methods. Antibody was administered the day before, 2 hr before, and the day after grafting. Results. Antibody administration on the day before, 2 hr before, and the day after grafting significantly prolonged vascularized cardiac allograft survival. Importantly, treatment recognizing recipient MHC was effective, whereas a similar regimen recognizing donor MHC was not. Conclusions. Noncytotoxic recipient MHC class II-specific antibodies modify allograft rejection. Possible mechanisms for this therapeutic effect are discussed.